Please assess the completion status of the following clinical trial:

Trial Title: First Line Osimertinib in the Real World: an Inter-regional Prospective Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* histological confirmed diagnosis of NSCLC and EGFR mutation in exon 18-21;~* locally advanced inoperable or metastatic disease (stage III and IV according to 8th edition of the TNM classification for lung cancer);~* first line treatment with the third generation EGFR TKI, osimertinib;~* age \>18 years~* written informed consent~Exclusion Criteria:~Patients who receive study drugs in clinical trials will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Untreated EGFR-mutant advanced non-small-cell lung cancer patients (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).